Syros Pharmaceuticals Inc SYRS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
5.13UNCH (UNCH)
Volume
41,501
Close
5.13quote price arrow down-0.07 (-1.35%)
Volume
53,247
52 week range
2.09 - 8.17
Loading...
  • Open5.15
  • Day High5.34
  • Day Low5.05
  • Prev Close5.20
  • 52 Week High8.17
  • 52 Week High Date01/02/24
  • 52 Week Low2.09
  • 52 Week Low Date10/19/23

Key Stats

  • Market Cap137.116M
  • Shares Out26.73M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta1.73
  • YTD % Change-34.15

KEY STATS

  • Open5.15
  • Day High5.34
  • Day Low5.05
  • Prev Close5.20
  • 52 Week High8.17
  • 52 Week High Date01/02/24
  • 52 Week Low2.09
  • 52 Week Low Date10/19/23
  • Market Cap137.116M
  • Shares Out26.73M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta1.73
  • YTD % Change-34.15

RATIOS/PROFITABILITY

  • EPS (TTM)-5.77
  • P/E (TTM)-0.89
  • Fwd P/E (NTM)-1.39
  • EBITDA (TTM)-124.247M
  • ROE (TTM)-227.95%
  • Revenue (TTM)9.935M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,656.51%
  • Debt To Equity (MRQ)247.41%

EVENTS

  • Earnings Date05/08/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Syros Pharmaceuticals Inc

 

Profile

MORE
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk...
Peter Wirth J.D.
Independent Chairman of the Board
Conley Chee
President, Chief Executive Officer, Director
Jason Haas
Chief Financial Officer
Address
35 Cambridge Park Drive
Cambridge, MA
02140
United States

Top Peers

SYMBOLLASTCHG%CHG
VXRT
Vaxart Inc
0.7289-0.0201-2.6836%
COYA
Coya Therapeutics Inc
8.68-0.10-1.14%
MCRB
Seres Therapeutics Inc
1.16+0.05+4.50%
PRQR
ProQR Therapeutics NV
2.01+0.02+1.01%
OMGA
Omega Therapeutics Inc
2.58-0.18-6.52%